Vernalis Research Limited

Ian Anthony Cliffe

David Reginald Adams

Howard Langham Mansell

Nathaniel Monck

Jonathan Richard Anthony Roffey

James Edward Paul Davidson

Jonathan Mark Bentley

Corinna Dagmar Bodkin

Richard John Hamlyn

Robin Gerald Shepherd

Roger John Gillespie

Joanne Lerpiniere

Suneel Gaur

Matthew Alexander James Duncton

Ashley Roger George

Lars Jacob Stray Knutsen

Jon Mark Bentley

Paul Richard Giles

Michael John Bickerdike

By Joy Miriam Shepherd

A compound of formula (1) wherein R is aryl; and R is hydrogen or alkyl; pharmaceutically acceptable addition compounds thereof; and their use in therapy, particularly for the treatment and prophylaxis of CNS disorders such as anxiety and epilepsy.

Azetidinecarboxamide derivatives for treating CNS disorders

A chemical compound of formula (I) wherein: R and R are independently selected from hydrogen and alkyl; R is alkyl; R , R and R are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsufoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; R is selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; A is a 5- or 6-membered partially unsaturated or aromatic heterocyclic ring or a 5- or 6-membered partially unsaturated carbocyclic ring, wherein if A is a 6-membered partially unsaturated carbocyclic ring then at least one of R to R is other than hydrogen, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof, and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinial disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal application

Use of a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A receptors, may be beneficial, such as a movement disorder, for example, Parkinson's Disease or progressive supemuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorder-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.

4-quinolinemethanol derivatives as purine receptor antagonists (II)

Azetidinecarboxamide derivatives for the treatment of CNS disorders

A chemical compound of formula (I), wherein n is 1, 2 or 3; R and R are independently selected from hydrogen and alkyl; R is alkyl; R to R are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, or R and R together form a carbocyclic or heterocyclic ring, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity

Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

 A chemical compound of formula (I), wherein R to R are independently selected from hydrogen and alkyl; R is selected from hydrogen, alkyl, alkoxy, formyl and cyano; X is selected from N and C&mdash;R ; X is selected from N and C&mdash;R ; X is selected from N and C&mdash;R ; X is selected from N and C&mdash;R ; wherein at least one of X , X , X and X is N; and R to R are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus; and sleep apnea, and particularly for the treatment of obesity.

Pyrroloquinolines for treatment of obesity

Growing community of inventors

Wokingham, United Kingdom

Ian Anthony Cliffe